Skip to main content

The Globe and Mail

J&J beats forecast, takes new charge for recalled hips

In this Oct. 10, 2008 file photo illustration, Johnson & Johnson products are shown in Philadelphia.

Matt Rourke/AP

Johnson & Johnson reported better-than-expected fourth-quarter earnings on Tuesday, fuelled by rebounding sales of prescription drugs and demand for its medical devices, but took another big special charge for its recalled artificial hips.

The diversified health care company on Tuesday said it earned $2.6-billion (U.S.), or 91 cents per share. That compared with $218-million, or 8 cents per share, in the year-ago period when the company took charges of more than $3-billion, including $800-million for medical costs related to recalls of defective "metal-on-metal" hip replacement devices made by its DePuy Orthopedics unit.

Excluding special items, J&J earned $1.19 per share. Analysts, on average, expected $1.17 per share.

Story continues below advertisement

Global revenue rose 8 per cent to $17.56-billion, below Wall Street expectations of $17.7-billion.

Report an error
Comments

The Globe invites you to share your views. Please stay on topic and be respectful to everyone. For more information on our commenting policies and how our community-based moderation works, please read our Community Guidelines and our Terms and Conditions.

We’ve made some technical updates to our commenting software. If you are experiencing any issues posting comments, simply log out and log back in.

Discussion loading… ✨

Combined Shape Created with Sketch.

Combined Shape Created with Sketch.

Thank you!

You are now subscribed to the newsletter at

You can unsubscribe from this newsletter or Globe promotions at any time by clicking the link at the bottom of the newsletter, or by emailing us at privacy@globeandmail.com.